|
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia Clinical research trials and Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia. Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia clinical trial. Test subjects typically receive the most expert healthcare available for their Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia  Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
For Condition: untreated childhood acute lymphoblastic leukemia,L1 childhood acute lymphoblastic leukemia,L2 childhood acute lymphoblastic leukemia,L3 childhood acute lymphoblastic leukemia
Status: Recruiting
Sponsor(s): Children's Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapyregimen is most effective for childhood acute lymphoblastic leukemia. PURPOSE: Randomizedphase III trial to compare the effectiveness of different combination chemotherapy regimens in treating children who have acute lymphoblastic leukemia.
Details: OBJECTIVES: - Compare the event-free survival and overall survival of children with standard-risk acute lymphoblastic leukemia treated with escalating-dose IV methotrexate without leucovorin calcium versus oral methotrexate during the interim maintenance phase of therapy. - Compare the event-free survival and overall survival of these patients after receiving treatment in two delayed intensification phases versus one delayed intensification phase. - Compare the toxic effects of oral versus escalating-dose intravenous methotrexate in these patients. - Determine the prognostic significance of the rate of disappearance of peripheral lymphoblasts and lymphocytes during the first week of treatment in these patients. - Determine the prognostic significance of trisomies of chromosomes 4, 5, 10, and 17 and early treatment response in patients treated with these regimens. - Determine the prognostic significance of the TEL-AML1 fusion transcript and early treatment response in patients treated with these regimens. - Determine the minimal residual disease (MRD) by polymerase chain reaction in bone marrow and cerebrospinal fluid at various stages of therapy in these patients. - Determine the prognostic significance of MRD during various stages of therapy in these patients. - Determine whether a second delayed intensification therapy improves the prognosis of patients who have MRD at the end of induction therapy. OUTLINE: This is a randomized, multicenter study. Patients without CNS disease at diagnosis, achieving a specified early marrow response profile and M1 marrow status of less than 5% blasts in the bone marrow (regardless of the proportion of mature lymphocytes) by day 28 of induction therapy, and remaining event free with favorable bone marrow status and cytogenetics between day 21 and 28 of consolidation therapy are randomized to one of four treatment arms. Patients with CNS disease at diagnosis are assigned to treatment arm II and undergo cranial irradiation. Patients with any of the following unfavorable bone marrow features and/or unfavorable cytogenetic features are assigned to the augmented treatment regimen by day 21 of induction chemotherapy or at the beginning of consolidation chemotherapy: NOTE: All T-cell precursor patients that are not more than 4 months past completion of the delayed intensification phase of therapy should be switched to the augmented regimen as of 3/8/2004. These patients may be switched to the augmented regimen as late as day 21. Otherwise they should start the augmented therapy in the consolidation phase. - 5-25% blasts in bone marrow at day 28 of induction chemotherapy (or at day 14 of induction chemotherapy if day 7 status is M3) OR - M3: More than 25% blast cell in bone marrow, regardless of the proportion of mature lymphocytes at day 14 of induction chemotherapy - Must have 1 of the following: - t(9;22)(q34;q11) - t(4;11)(q21;q23) - Balanced t(1;19)(q23;p13) - Hypodiploidy with less than 45 chromosomes - Other 11q23 translocations involving MLL Patients receive standard induction chemotherapy comprising cytarabine (ARA-C) intrathecally (IT) on day 0 or up to 72 hours before day 0; oral dexamethasone (DM) twice daily on days 0-27; vincristine (VCR) IV on days 0, 7, 14, and 21; and pegaspargase (PEG-ASP) intramuscularly (IM) once between days 3-5. Patients without CNS disease at diagnosis receive methotrexate (MTX) IT on days 7 and 28. Patients with CNS disease at diagnosis receive MTX IT on days 7, 14, 21, and 28. Patients who have achieved M1 marrow status by day 28 of induction therapy and have favorable early bone marrow response and cytogenetics proceed to standard consolidation therapy once blood counts have recovered. Patients with M3 bone marrow status at day 28 of induction therapy are taken off the protocol. All other patients are assigned to the augmented treatment regimen. Beginning on day 28 of induction chemotherapy, patients receive standard consolidation chemotherapy comprising VCR IV on day 0 and oral mercaptopurine (MP) on days 0-27. Patients without CNS disease at diagnosis receive MTX IT on days 7, 14, 21, and 28. Patients with CNS disease at diagnosis receive MTX IT on day 7 and cranial irradiation 5 days a week for 2 weeks. Patients with testicular disease receive bilateral testicular radiotherapy 5 days a week for 1 week and then for 3 consecutive days during the next week. NOTE: As of 3/8/2004, patients with T-cell disease who did not achieve M1 marrow status by day 14 of induction OR who did not receive augmented induction and/or consolidation (regardless of early marrow status) receive cranial irradiation. - Beginning on day 28 of consolidation chemotherapy, patients receive interim maintenance I chemotherapy comprising oral DM twice daily on days 0-4 and 28-32; VCR IV on days 0 and 28; oral MTX on days 0, 7, 14, 21, 28, 35, 42, and 49; oral MP on days 0-49; and MTX IT on day 28. Beginning on day 56 of interim maintenance I chemotherapy, patients receive delayed intensification chemotherapy comprising oral DM twice daily on days 0-6 and 14-20; VCR IV and doxorubicin (DOX) IV over 15 minutes to 2 hours on days 0, 7, and 14; PEG-ASP IM on day 3; cyclophosphamide (CTX) IV over 20-30 minutes on day 28; oral thioguanine (TG) on days 28-41; ARA-C IV or subcutaneously (SC) daily on days 28-31 and 35-38; and MTX IT on days 0 and 28. Beginning on day 56 of delayed intensification chemotherapy, patients receive interim maintenance II chemotherapy identical to interim maintenance I chemotherapy except patients receive MTX IT on days 0 and 28. Beginning on day 56 of interim maintenance II chemotherapy, patients receive maintenance chemotherapy comprising oral DM twice daily on days 0-4, 28-32, and 56-60; VCR IV on days 0, 28, and 56; oral MP on days 0-83; oral MTX on days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, and 77; and MTX IT on day 0. - Arm II: Patients receive interim maintenance I chemotherapy, delayed intensification chemotherapy, and interim maintenance II chemotherapy as in arm I. Beginning on day 56 of interim maintenance II chemotherapy, patients then receive a second course of delayed intensification chemotherapy followed by maintenance chemotherapy as in arm I. - Arm III: Beginning on day 28 of consolidation chemotherapy, patients receive interim maintenance I chemotherapy comprising VCR IV; escalating doses of MTX IV on days 0, 10, 20, 30, and 40; and MTX IT on day 30. Patients then receive delayed intensification chemotherapy as in arm I. Patients receive interim maintenance II chemotherapy as in interim maintenance I chemotherapy, but with IV MTX starting at 2/3 of the maximum tolerated dose (MTD) attained in interim maintenance I chemotherapy. Patients then receive maintenance chemotherapy as in arm I. - Arm IV: Patients receive interim maintenance I chemotherapy as in arm III, delayed intensification chemotherapy as in arm I, interim maintenance II chemotherapy as in arm III, delayed intensification II chemotherapy as in arm II, and maintenance chemotherapy as in arm I. - Patients receive induction chemotherapy comprising daunorubicin IV continuously for 48 hours beginning no later than day 21; oral DM twice daily on days 14-27; and VCR IV on days 14 and 21. Patients without CNS disease at diagnosis receive MTX IT on days 21 and 35. Patients with CNS disease at diagnosis receive MTX IT on days 21 and 28. NOTE: Patients with T-cell disease should re-start with augmented consolidation and proceed as per the augmented regimen. Beginning on day 35 of induction chemotherapy, patients receive consolidation therapy comprising CTX IV over 20-30 minutes on days 0 and 28; oral MP on days 0-13 and 28-41; ARA-C IV or SC daily on days 0-3, 7-10, 28-31, and 35-38; VCR IV on days 14, 21, 42, and 49; and PEG-ASP IM on days 14 and 42. Patients without CNS disease at diagnosis receive MTX IT on days 7, 14, and 21. Patients with CNS disease at diagnosis receive MTX IT on day 7 and cranial irradiation as in the randomized treatment section. Patients with testicular leukemia receive radiotherapy as in the randomized treatment section. Beginning on day 63 of consolidation chemotherapy, patients receive interim maintenance I chemotherapy comprising VCR IV on days 0, 10, 20, 30, and 40; escalating doses of MTX IV on days 10, 20, 30, and 40; PEG-ASP IM on days 1 and 21; and MTX IT on days 0 and 30. Beginning on day 56 of interim maintenance I chemotherapy, patients receive delayed intensification I chemotherapy comprising oral DM twice daily on days 0-6 and 14-20; VCR IV on days 0, 7, 14, 42, and 49; DOX IV over 15 minutes to 2 hours on days 0, 7, and 14; PEG-ASP IM on days 3 and 42; CTX IV over 20-30 minutes on day 28; oral TG on days 28-41; ARA-C IV or SC daily on days 28-31 and 35-38; and MTX IT on days 0 and 28. NOTE: Patients with T-cell disease who are in interim maintenance I chemotherapy with escalating IV methotrexate should continue this phase and then proceed as per the augmented regimen. If these patients are receiving conventional interim maintenance chemotherapy with oral methotrexate, they should stop and restart the interim maintenance as per the augmented regimen. These patients receive cranial irradiation starting on day 28 of delayed intensification II chemotherapy. Beginning on day 56 of delayed intensification I chemotherapy, patients receive interim maintenance II chemotherapy as in interim maintenance I chemotherapy, but with IV MTX starting at 2/3 of the MTD attained in interim maintenance I chemotherapy. NOTE: Patients with T-cell disease who are in delayed intensification I chemotherapy proceed with this phase, with the addition of 2 vincristine doses on days 42 and 49 and PEG-ASP on day 42. These patients then proceed as per the augmented regimen with the addition of cranial irradiation starting on day 28 of delayed intensification II chemotherapy. NOTE: Patients with T-cell disease who are within 4 months of completing delayed intensification I chemotherapy and have not received interim maintenance II chemotherapy with escalating IV methotrexate or delayed intensification II chemotherapy receive a course of interim maintenance chemotherapy and delayed intensification II chemotherapy according to the augmented regimen. If these patients have received interim maintenance II chemotherapy with escalating IV methotrexate, they receive delayed intensification II chemotherapy according to the augmented regimen. These patients also receive cranial irradiation starting on day 28 of delayed intensification II chemotherapy and then proceed to maintenance therapy. Beginning on day 56 of interim maintenance II chemotherapy, patients receive delayed intensification II chemotherapy as in delayed intensification I chemotherapy. Beginning on day 56 of delayed intensification II chemotherapy, patients receive maintenance chemotherapy comprising oral DM twice daily on days 0-4, 28-32, and 56-60; VCR IV on days 0, 28, and 56; oral MP on days 0-83; oral MTX on days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, and 77; and MTX IT on day 0. Patients are followed every 4-8 weeks for one year, every 3 months for one year, every 6 months for one year, and then annually thereafter. PROJECTED ACCRUAL: A total of 2,037 randomized patients will be accrued for this study within 3.75 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 1 Year/9 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of previously untreated B-cell precursor acute lymphoblastic leukemia - More than 25% L1 or L2 lymphoblasts - No more than 25% L3 lymphoblasts - WBC < 50,000/mm^3 - No T-cell precursor acute lymphoblastic leukemia by immunophenotyping - Massive lymphadenopathy, massive splenomegaly, or large mediastinal mass allowed - CNS or testicular leukemia allowed - No patients found to have t(8;14)(q24;q32), t(8;22)(q24;q11), and t(2;8)(p11-p12;q24) (characteristic of Burkitt's lymphoma) PATIENT CHARACTERISTICS: Age: - 1 to 9 Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - See Disease Characteristics Hepatic: - Not specified Renal: - Not specified Other: - Not pregnant - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No more than 72 hours since prior intrathecal cytarabine Endocrine therapy: - At least 30 days since prior systemic corticosteroids given for more than 48 hours - Prior corticosteroids for mediastinal mass causing superior mediastinal syndrome allowed - Prior or concurrent inhaled corticosteroids allowed Radiotherapy: - Prior radiotherapy for mediastinal mass causing superior mediastinal syndrome allowed - No concurrent spinal radiotherapy Surgery: - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
YousifMatloub, Study Chair, University of Wisconsin Comprehensive Cancer Center
Children's Hospital of Orange County *Recruiting*
Orange, California, 92868
United States
Recruiting Wei-Ping Shen 714-532-8636
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Peter Steinherz 212-639-7951
Covenant Children's Hospital *Recruiting*
Lubbock, Texas, 79410
United States
Recruiting John Iacuone 806-725-1011
Children's Hospital of Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19104
United States
Recruiting Beverly Lange 215-590-2249
Josephine Ford Cancer Center at Henry Ford Hospital *Recruiting*
Detroit, Michigan, 48202
United States
Recruiting Hassan Yaish 313-916-3138
Blumenthal Cancer Center at Carolinas Medical Center *Recruiting*
Charlotte, North Carolina, 28232-2861
United States
Recruiting Daniel McMahon 704-355-1130
Mountain States Tumor Institute - Boise *Recruiting*
Boise, Idaho, 83712
United States
Recruiting J. Johnston 208-381-2782
Royal Children's Hospital *Recruiting*
Brisbane, Queensland, 4029
Australia
Recruiting Liane Lockwood 617-363-61356
Southern California Permanente Medical Group *Recruiting*
Downey, California, 90242
United States
Recruiting Willye Powell 562-803-2472
Children's Hospital and Research Center at Oakland *Recruiting*
Oakland, California, 94609-1809
United States
Recruiting James Feusner 510-428-3000
Long Island Cancer Center at Stony Brook University Hospital *Recruiting*
Stony Brook, New York, 11794
United States
Recruiting Robert Parker 631-689-6000
Kaiser Permanente Medical Center - San Francisco Geary Campus *Recruiting*
San Francisco, California, 94115
United States
Recruiting Kenneth Leung 415-833-3528
Meritcare Roger Maris Cancer Center *Recruiting*
Fargo, North Dakota, 58122
United States
Recruiting Nathan Kobrinsky 701-234-2735
Ireland Cancer Center *Recruiting*
Cleveland, Ohio, 44106-5065
United States
Recruiting Eric Kodish 216-844-5432
Marshfield Clinic *Recruiting*
Marshfield, Wisconsin, 54449-5772
United States
Recruiting H. Nickerson 715-387-5018
Markey Cancer Center at University of Kentucky Chandler Medical Center *Recruiting*
Lexington, Kentucky, 40536-0284
United States
Recruiting Martha Greenwood 859-323-6771
Janeway Children's Health and Rehabilitation Centre *Recruiting*
St. John's, Newfoundland and Labrador, A1B 3V6
Canada
Recruiting John Hand 709-777-4799
Raymond Blank Memorial Hospital for Children *Recruiting*
Des Moines, Iowa, 50308
United States
Recruiting Torrey Mitchell 515-241-8912
Swiss Pediatric Oncology Group Bern *Recruiting*
Bern, , CH 3010
Switzerland
Recruiting Annette Ridolfi-Luethy 41-31-632-9372
St. Joseph's Hospital and Medical Center *Recruiting*
Paterson, New Jersey, 07503
United States
Recruiting Mary Bonilla 973-754-3230
CCOP - Scott and White Hospital *Recruiting*
Temple, Texas, 76508
United States
Recruiting Lucas Wong 254-724-7048
Children's National Medical Center *Recruiting*
Washington D.C., District of Columbia, 20010-2970
United States
Recruiting Nita Seibel 202-884-2144
Children's Hospital Medical Center of Akron *Recruiting*
Akron, Ohio, 44308
United States
Recruiting Jeffrey Hord 330-543-8580
North Shore University Hospital *Recruiting*
Manhasset, New York, 11030
United States
Recruiting Indira Sahdev 718-470-3460
Kosair Children's Hospital *Recruiting*
Louisville, Kentucky, 40202-3830
United States
Recruiting Salvatore Bertolone 502-852-8450
East Tennessee State University Cancer Center at Johnson City Medical Center *Recruiting*
Johnson City, Tennessee, 37604
United States
Recruiting Sharon Castellino 423-433-6200
CCOP - Marshfield Clinic Research Foundation *Recruiting*
Marshfield, Wisconsin, 54449
United States
Recruiting Tarit Banerjee 715-387-5134
University of Illinois Medical Center *Recruiting*
Chicago, Illinois, 60612
United States
Recruiting Mary Schmidt 312-996-6143
St. Vincent Mercy Medical Center *Recruiting*
Toledo, Ohio, 43608
United States
Recruiting Rama Jasty 419-251-8215
Starship Children's Hospital *Recruiting*
Auckland, ,
New Zealand
Recruiting Lochie Teague 64-9-307-4949 ext. 6295
Cincinnati Children's Hospital Medical Center *Recruiting*
Cincinnati, Ohio, 45229-3039
United States
Recruiting John Perentesis 513-636-6090
Children's Hospital of Denver *Recruiting*
Denver, Colorado, 80218-1088
United States
Recruiting Roger Giller 303-861-6892
Bellin Memorial Hospital *Recruiting*
Green Bay, Wisconsin, 54301
United States
Recruiting Dorothy Ganick 920-433-6025
City of Hope Comprehensive Cancer Center *Recruiting*
Duarte, California, 91010-3000
United States
Recruiting Judith Sato 626-930-5430
Sydney Children's Hospital *Recruiting*
Randwick, New South Wales, 2031
Australia
Recruiting Glenn Marshall 61-2-9382-1721
Medical Center of Central Georgia *Recruiting*
Macon, Georgia, 31201
United States
Recruiting Hassan Dannawi 478-633-1104
IWK Health Centre *Recruiting*
Halifax, Nova Scotia, B3J 3G9
Canada
Recruiting Dorothy Barnard 902-470-8291
Rhode Island Hospital *Recruiting*
Providence, Rhode Island, 02818
United States
Recruiting William Ferguson 401-444-5171
Children's Medical Center - Dayton *Recruiting*
Dayton, Ohio, 45404
United States
Recruiting Emmett Broxson 937-641-3111
Children's Hospitals and Clinics - Minnesota *Recruiting*
St. Paul, Minnesota, 55102
United States
Recruiting Christopher Moertel 651-220-6041
CCOP - Columbia River Oncology Program *Recruiting*
Portland, Oregon, 97225
United States
Recruiting Keith Lanier 503-216-6260
Children's Hospital of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania, 15213
United States
Recruiting Arthur Ritchey 412-692-5949
University of Wisconsin Comprehensive Cancer Center *Recruiting*
Madison, Wisconsin, 53792-6164
United States
Recruiting Diane Puccetti 608-263-0320
Spectrum Health and DeVos Children's Hospital *Recruiting*
Grand Rapids, Michigan, 49503
United States
Recruiting David Freyer 616-391-2086
Children's Hospital of Western Ontario *Recruiting*
London, Ontario, N6C 2V5
Canada
Recruiting Anne Lois Cairney 519-685-8494
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center *Recruiting*
Nashville, Tennessee, 37232-6838
United States
Recruiting James Whitlock 615-936-1762
St. Barnabas Medical Center *Recruiting*
Livingston, New Jersey, 07039
United States
Recruiting Brenda Sison 973-322-2800
Children's Hospital Los Angeles *Recruiting*
Los Angeles, California, 90027-0700
United States
Recruiting Paul Gaynon 323-669-2163
Geisinger Medical Center *Recruiting*
Danville, Pennsylvania, 17822-1320
United States
Recruiting Jeffrey Taylor 570-271-6848
British Columbia Children's Hospital *Recruiting*
Vancouver, British Columbia, V6H 3V4
Canada
Recruiting Paul Rogers 604-875-2322
Cancer Institute of New Jersey *Recruiting*
New Brunswick, New Jersey, 08903
United States
Recruiting Richard Drachtman 732-235-7898
Lutheran General Cancer Care Center *Recruiting*
Park Ridge, Illinois, 60068-1174
United States
Recruiting Jong-Hyo Kwon 847-723-5962
New York Medical College *Recruiting*
Valhalla, New York, 10595
United States
Recruiting M. Ozkaynak 914-493-7997
Texas Tech University Health Sciences Center School of Medicine *Recruiting*
Amarillo, Texas, 79106
United States
Recruiting Curtis Turner 806-354-5434
East Tennessee Children's Hospital *Recruiting*
Knoxville, Tennessee, 37901
United States
Recruiting Ray Pais 865-541-8266
Alfred I. duPont Hospital for Children *Recruiting*
Wilmington, Delaware, 19899
United States
Recruiting Gregory Griffin 302-651-5500
Sunrise Hospital and Medical Center *Recruiting*
Las Vegas, Nevada, 89109
United States
Recruiting Jonathan Bernstein 702-732-0971
Children's Hospital of Austin *Recruiting*
Austin, Texas, 78701
United States
Recruiting Sharon Lockhart 512-324-8480
Children's Mercy Hospital *Recruiting*
Kansas City, Missouri, 64108
United States
Recruiting Maxine Hetherington 816-234-3265
New York Weill Cornell Cancer Center at Cornell University *Recruiting*
New York City, New York, 10021
United States
Recruiting Patricia Giardina 212-746-3400
Herbert Irving Comprehensive Cancer Center at Columbia University *Recruiting*
New York City, New York, 10032
United States
Recruiting Linda Granowetter 212-305-8652
Sinai Hospital of Baltimore *Recruiting*
Baltimore, Maryland, 21225
United States
Recruiting Joseph Wiley 410-601-5864
Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center *Recruiting*
Orange, California, 92868
United States
Recruiting Stanley Calderwood 714-456-6615
University of Minnesota Cancer Center *Recruiting*
Minneapolis, Minnesota, 55455
United States
Recruiting Joseph Neglia 612-625-6903
St. Mary's - Duluth Clinic Cancer Center *Recruiting*
Duluth, Minnesota, 55805
United States
Recruiting Jacquelyn Wiermaa 218-786-3625
Children's Hospital of the King's Daughters *Recruiting*
Norfolk, Virginia, 23507
United States
Recruiting Rebecca Byrd 757-668-7243
CancerCare Manitoba *Recruiting*
Winnipeg, Manitoba, R3E 0V9
Canada
Recruiting Rochelle Yanofsky 204-787-4163
Loma Linda University Cancer Institute at Loma Linda University Medical Center *Recruiting*
Loma Linda, California, 92354
United States
Recruiting Antranik Bedros 909-558-3391
Children's Hospital and Regional Medical Center - Seattle *Recruiting*
Seattle, Washington, 98105
United States
Recruiting Douglas Hawkins 206-987-3096
Children's Hospital Central California *Recruiting*
Madera, California, 93638-8762
United States
Recruiting Vonda Crouse 559-353-5480
University of Texas - MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030-4009
United States
Recruiting Joann Ater 713-792-6665
Brookdale University Hospital and Medical Center *Recruiting*
Brooklyn, New York, 11212
United States
Recruiting Kusum Viswanathan 718-240-5904
University of Chicago Cancer Research Center *Recruiting*
Chicago, Illinois, 60601
United States
Recruiting James Nachman 773-702-6808
UCSF Comprehensive Cancer Center *Recruiting*
San Francisco, California, 94115
United States
Recruiting Katherine Matthay 415-353-9510
Santa Barbara Cottage Hospital *Recruiting*
Santa Barbara, California, 93102
United States
Recruiting Felicity Hodder 805-569-8394
Newark Beth Israel Medical Center *Recruiting*
Newark, New Jersey, 07112-2094
United States
Recruiting Peri Kamalakar 973-926-7161
Mayo Clinic Cancer Center *Recruiting*
Rochester, Minnesota, 55905
United States
Recruiting Carola Arndt 507-284-4822
Breslin Cancer Center at Ingham Regional Medical Center *Recruiting*
Lansing, Michigan, 48910
United States
Recruiting Renuka Gera 517-334-2337
Deaconess Medical Center *Recruiting*
Spokane, Washington, 99210-0248
United States
Recruiting Steven Bergstrom 509-473-7012
Presbyterian-St Luke's Medical Center *Recruiting*
Denver, Colorado, 80218
United States
Recruiting Stephen Palmer 719-471-2462
Medical City Dallas Hospital *Recruiting*
Dallas, Texas, 75230
United States
Recruiting Carl Lenarsky 214-788-6647
Albert Einstein Clinical Cancer Center *Recruiting*
Bronx, New York, 10461
United States
Recruiting Eva Radel 718-920-7844
Dakota Cancer Institute at Innovis Health - Dakota Clinic *Recruiting*
Fargo, North Dakota, 58103-4940
United States
Recruiting Janet Tillisch 701-364-4966
Bronson Methodist Hospital *Recruiting*
Kalamazoo, Michigan, 49007
United States
Recruiting Leonard Mattano 269-341-6350
Cabell Huntington Hospital *Recruiting*
Huntington, West Virginia, 25701
United States
Recruiting Andrew Pendleton 304-691-1384
Princess Margaret Hospital for Children *Recruiting*
Perth, Western Australia, 6001
Australia
Recruiting David Baker 61-8-9340-8234
CCOP - Beaumont *Recruiting*
Royal Oak, Michigan, 48073-6769
United States
Recruiting David Decker 248-551-7695
Saskatoon Cancer Centre *Recruiting*
Saskatoon, Saskatchewan, S7N 4H4
Canada
Recruiting Ali Kaiser 306-655-2684
Penn State Cancer Institute at Milton S. Hershey Medical Center *Recruiting*
Hershey, Pennsylvania, 17033-0850
United States
Recruiting John Neely 717-531-6012
Southern Illinois University School of Medicine *Recruiting*
Springfield, Illinois, 62794-9658
United States
Recruiting Gregory Brandt 217-545-5817
University Hospital at State University of New York - Upstate Medical University *Recruiting*
Syracuse, New York, 13210
United States
Recruiting Ronald Dubowy 315-464-5294
Phoenix Children's Hospital *Recruiting*
Phoenix, Arizona, 85016
United States
Recruiting Dale Singer 602-546-0920
Yale Comprehensive Cancer Center *Recruiting*
New Haven, Connecticut, 06520-8028
United States
Recruiting Jack Hoff 203-785-4095
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center *Recruiting*
La Crosse, Wisconsin, 54601
United States
Recruiting Robert Ettinger 608-782-7300
UNMC Eppley Cancer Center at the University of Nebraska Medical Center *Recruiting*
Omaha, Nebraska, 68198-2168
United States
Recruiting Peter Coccia 402-559-7257
Cancer Center of Albany Medical Center *Recruiting*
Albany, New York, 12208
United States
Recruiting Jennifer Pearce 518-262-5513
State University of New York Health Science Center at Brooklyn College of Medicine *Recruiting*
Brooklyn, New York, 11203
United States
Recruiting Sreedhar Rao 718-270-1693
William Beaumont Hospital - Royal Oak *Recruiting*
Royal Oak, Michigan, 48073-6769
United States
Recruiting Charles Main 248-551-0360
Indiana University Cancer Center *Recruiting*
Indianapolis, Indiana, 46202-5289
United States
Recruiting Robert Fallon 317-274-8784
Mary Bridge Children's Health Center *Recruiting*
Tacoma, Washington, 98415-0299
United States
Recruiting William Thomas 253-403-4915
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill *Recruiting*
Chapel Hill, North Carolina, 27599-7295
United States
Recruiting Stuart Gold 919-966-0985
West Virginia University - Robert C. Byrd Health Sciences Center - Charleston Division *Recruiting*
Charleston, West Virginia, 25302
United States
Recruiting Sanjeev Grover 304-388-1540
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus *Recruiting*
Atlanta, Georgia, 30342
United States
Recruiting Stephen Lauer 404-250-2781
Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego *Recruiting*
San Diego, California, 92120
United States
Recruiting Wellington Loh 619-516-6144
Children's Hospital of Columbus *Recruiting*
Columbus, Ohio, 43205-2696
United States
Recruiting Amanda Termuhlen 614-722-3552
Doernbecher Children's Hospital at Oregon Health & Science University *Recruiting*
Portland, Oregon, 97239-3098
United States
Recruiting H. Nicholson 503-494-1543
Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center *Recruiting*
Savannah, Georgia, 31405
United States
Recruiting Tribhawan Vats 912-350-8194
University of Michigan Comprehensive Cancer Center *Recruiting*
Ann Arbor, Michigan, 48109-0914
United States
Recruiting Raymond Hutchinson 734-936-8785
Toledo Children's Hospital *Recruiting*
Toledo, Ohio, 43601
United States
Recruiting Richard Shore 419-471-5437
Group Health Central Hospital *Recruiting*
Seattle, Washington, 98112
United States
Recruiting Philip Herzog 425-883-5291
Schneider Children's Hospital *Recruiting*
New Hyde Park, New York, 11042
United States
Recruiting Arlene Redner 718-470-3460
Jonsson Comprehensive Cancer Center, UCLA *Recruiting*
Los Angeles, California, 90095-1781
United States
Recruiting Stephen Feig 310-825-5268
Swiss Pediatric Oncology Group Lausanne *Recruiting*
Lausanne, , CH 1011
Switzerland
Recruiting Maja Popovic 41-21-314-3567
Holden Comprehensive Cancer Center at University of Iowa *Recruiting*
Iowa City, Iowa, 52242-1009
United States
Recruiting Raymond Tannous 319-356-1905
MBCCOP - LSU Health Sciences Center *Recruiting*
New Orleans, Louisiana, 70112
United States
Recruiting Jill Gilbert 504-568-5136
Sioux Valley Hospital at University of South Dakota Medical Center *Recruiting*
Sioux Falls, South Dakota, 57117
United States
Recruiting Jakica Tancabelic 605-333-7171
University of Connecticut Cancer Center at University of Connecticut Health Center *Recruiting*
Farmington, Connecticut, 06360-7106
United States
Recruiting Arnold Altman 860-545-9630
Children's Hospitals and Clinics - Minneapolis *Recruiting*
Minneapolis, Minnesota, 55404
United States
Recruiting Maura O'Leary 612-813-5940
Kaiser Permanente Medical Center - Santa Clara *Recruiting*
Santa Clara, California, 95051-5386
United States
Recruiting Carolyn Russo 408-236-5028
Baystate Medical Center *Recruiting*
Springfield, Massachusetts, 01107
United States
Recruiting David Steele 413-794-9338
Methodist Cancer Center at Methodist Specialty and Transplant Hospital *Recruiting*
San Antonio, Texas, 78229-3902
United States
Recruiting Jaime Estrada 210-575-8130
Lombardi Cancer Center at Georgetown University Medical Center *Recruiting*
Washington D.C., District of Columbia, 20007
United States
Recruiting Aziza Shad 202-687-2224
Brooklyn Hospital Center *Recruiting*
Brooklyn, New York, 11201-5493
United States
Recruiting Swayamprabha Sadanandan 718-250-6074
Maimonides Medical Center *Recruiting*
Brooklyn, New York, 11219
United States
Recruiting Ludovico Guarini 718-283-8173
Valerie Fund Children's Center at Atlantic Health *Recruiting*
Summit, New Jersey, 07901
United States
Recruiting Hazem Mahmoud 973-971-6731
Swiss Pediatric Oncology Group Geneva *Recruiting*
Geneva, , CH 1211
Switzerland
Recruiting Pierre Wacker 41-22-382-3311
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center *Recruiting*
Los Angeles, California, 90048
United States
Recruiting Moshe Arditi 310-423-4471
Children's Hospital of Omaha *Recruiting*
Omaha, Nebraska, 68114
United States
Recruiting Minnie Abromowitch 402-955-3950
Presbyterian Healthcare *Recruiting*
Charlotte, North Carolina, 28233
United States
Recruiting Mark Mogul 704-384-1900
David Grant Medical Center *Recruiting*
Travis Air Force Base, California, 94535
United States
Recruiting Peter Chenaille 707-423-7176
Allan Blair Cancer Centre *Recruiting*
Regina, Saskatchewan, S4T 7T1
Canada
Recruiting Christina Suan Goh 306-766-2205
Additional Information:
Study ID Numbers: CDR0000067855; COG-C1991,CCG-1991
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005945
Other L3 Childhood Acute Lymphoblastic Leukemia Studies:
1. Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
2. Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
3. Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
4. Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia
5. Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
Related Studies:
Other L3 childhood acute lymphoblastic leukemia Clinical Trials
Other New Jersey Clinical Trials
Other New Brunswick Clinical Trials
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
|
|
|
|
|
|
|
|
